Genetic Connective Tissue Disorders: A List of Conditions

Genetic connective tissue disorders encompass at least three dozen distinct conditions that affect the body’s structural scaffolding, from the collagen in your skin and blood vessels to the elastin in your lungs and the specialized membranes in your kidneys and eyes.¹ Because connective tissue exists virtually everywhere in the body, a single gene mutation can produce problems that span the heart, skeleton, skin, eyes, and internal organs at the same time. The most widely recognized names on the list, such as Ehlers-Danlos syndromes and Marfan syndrome, represent just a fraction of a much broader family of disorders.

The Common Thread

Connective tissue is the biological “glue and scaffolding” that supports and connects other tissues. Its main structural proteins include various types of collagen, elastin, and fibrillin, along with a mesh of other molecules collectively called the extracellular matrix. Mutations in the genes that code for these proteins, or for the enzymes that process and assemble them, cause the majority of heritable connective tissue disorders.² The consequences of any given mutation depend on where the affected protein is most abundant, what it does in that tissue, and how severely the mutation disrupts its function. That is why two people with mutations in the same gene can have dramatically different symptoms, and why conditions caused by mutations in different genes can look remarkably alike.

Ehlers-Danlos Syndromes

The Ehlers-Danlos syndromes (EDS) are probably the best-known family within this group. Rather than a single disease, EDS is an umbrella covering at least 13 to 14 recognized subtypes, most of which have been traced to mutations in about 20 genes.³ The majority of those genes encode fibrillar collagens (types I, III, and V) or the enzymes that modify and process them. Across subtypes, common features include unusually stretchy or fragile skin, joints that move well beyond the normal range, and tissue that bruises or tears easily.

The hypermobile type (hEDS) is by far the most common form, yet it is also the most diagnostically frustrating. Its molecular cause remains unknown, making it the only EDS subtype without an identified gene.³ Diagnosis relies entirely on clinical criteria established in 2017, and even among patients who meet those criteria, genetic testing reveals an alternative or additional diagnosis in roughly a quarter of cases, sometimes pointing toward conditions that require entirely different management.⁴ This means that a clinical label of hEDS should not be treated as the end of the diagnostic road.

Vascular EDS (vEDS), caused by mutations in the gene for type III collagen, sits at the other end of the severity spectrum. The soft connective tissues of blood vessel walls, the intestines, and other hollow organs are particularly affected. People with vEDS often present at a young age with spontaneous tears or ruptures of medium-sized arteries, and both open surgical repair and less invasive procedures carry high complication rates because the tissue is so fragile.⁵ Other subtypes, including classical EDS, kyphoscoliotic EDS, and dermatosparaxis EDS, each have their own characteristic patterns of skin, joint, and organ involvement, along with identified genetic causes.

Marfan Syndrome

Marfan syndrome results from mutations in the gene for fibrillin-1 (FBN1), a protein that forms tiny thread-like structures called microfibrils in the extracellular matrix.⁶ For years, the prevailing idea was that faulty fibrillin simply made tissues mechanically weaker. Research in mouse models showed that something else was going on: defective fibrillin-1 leads to overactivation of a signaling molecule called TGF-beta, which in turn drives cell death and tissue remodeling in the aorta, lungs, and other organs.⁷ That insight shifted the understanding of Marfan from a purely structural disease to one with a significant signaling component, and it opened the door to new treatment strategies.

Clinically, the two hallmark features are widening of the aortic root (the first stretch of the body’s main artery) and displacement of the lens of the eye. Under the revised Ghent diagnostic criteria, finding both of those features in someone with no family history is enough for a firm diagnosis.⁸ Other features, including tall stature with long limbs and fingers, a sunken or protruding chest, scoliosis, and stretch marks in unusual locations, can support the diagnosis but are not sufficient on their own. Aortic rupture remains the primary life-threatening risk, which is why regular heart imaging is a cornerstone of management.

The TGF-beta discovery led researchers to test losartan, a blood pressure medication that also damps down TGF-beta signaling. In a Marfan mouse model, losartan prevented aortic aneurysm formation and even partially reversed lung problems.⁹ Human clinical trials have since investigated losartan alongside or as an alternative to beta-blockers, the traditional first-line therapy for slowing aortic growth. The results in people have been more modest than the mouse data suggested, but losartan remains in clinical use for some Marfan patients, and the broader principle of targeting signaling pathways rather than just structural weakness continues to guide research across multiple connective tissue disorders.

Loeys-Dietz Syndrome

Loeys-Dietz syndrome (LDS) was first formally described in 2005 and shares enough features with Marfan syndrome that patients are sometimes initially misdiagnosed with one or the other. LDS is caused by mutations in the genes for TGF-beta receptors, primarily TGFBR1 and TGFBR2.¹⁰ The classic triad includes widespread arterial tortuosity (twisting of blood vessels) and aneurysms, widely spaced eyes, and a split uvula or cleft palate.¹¹

What makes LDS particularly dangerous is that aneurysms can occur throughout the arterial tree, not just in the aortic root as is typical of Marfan. They also tend to rupture at smaller diameters, so the thresholds for surgical intervention are generally lower. The connection to TGF-beta signaling is direct: the receptors themselves are defective, which paradoxically increases downstream TGF-beta activity, driving the same kind of destructive tissue remodeling seen in Marfan syndrome.¹² Genetic testing to distinguish LDS from Marfan is clinically important, because the two conditions can require different surveillance schedules and surgical timing.

Osteogenesis Imperfecta

Osteogenesis imperfecta (OI), sometimes called “brittle bone disease,” is best known for bones that fracture with little or no trauma. The most common forms result from mutations in the genes for type I collagen, but researchers have identified an expanding list of other genes that produce similar clinical pictures through different mechanisms. Despite this genetic diversity, the various forms share a core set of features that extend beyond the skeleton, including short stature, hearing loss, dental abnormalities, and blue-tinged whites of the eyes.¹³

Severity ranges enormously. Some people experience only a handful of fractures over a lifetime and may not receive a diagnosis until adulthood. Others are born with fractures already present and face life-threatening complications in infancy. Bisphosphonate medications, which slow bone breakdown, have been a mainstay of treatment for decades, but they address the downstream problem of bone loss rather than the root collagen defect. Newer approaches, including gene editing strategies, aim to correct the underlying mutation directly.

Conditions Beyond the Usual Headlines

Several genetic connective tissue disorders are far less familiar to the public but collectively affect a significant number of people.

Stickler Syndrome

Stickler syndrome is one of the more common hereditary connective tissue disorders, though it is frequently underdiagnosed. It involves mutations in collagen genes that are expressed in cartilage, the vitreous gel of the eye, and the inner ear. The most frequent form, caused by mutations in COL2A1, tends to produce a relatively mild high-frequency hearing loss in about half of those affected. Forms caused by mutations in COL11A1 or COL11A2 lead to more widespread and moderate hearing loss across all frequencies.¹⁴ Other hallmarks include severe near-sightedness with an increased risk of retinal detachment, a flattened midface, and early-onset arthritis.

Pseudoxanthoma Elasticum

Pseudoxanthoma elasticum (PXE) follows an autosomal recessive inheritance pattern, meaning a person needs to inherit a faulty copy of the ABCC6 gene from each parent to develop the disease.¹⁵ ABCC6 encodes a transport protein, and when it is missing or nonfunctional, calcium and other minerals accumulate in elastic fibers throughout the body. The visible result is often small yellowish bumps on the skin of the neck and body folds. More seriously, mineralized elastic fibers in the retina (Bruch’s membrane) can crack, causing progressive vision loss, and similar changes in blood vessel walls raise the risk of cardiovascular events.¹⁶

Cutis Laxa

Cutis laxa is a group of conditions in which the skin hangs in loose folds because elastic fibers fail to form or maintain their structure properly. Autosomal dominant forms are often caused by mutations in the elastin gene itself. Research has shown that these mutations produce abnormal elastin protein that is partly retained inside cells and partly secreted, interfering with the assembly of normal elastic fibers.¹⁷ Some forms involve severe lung disease because the same elastic fibers are critical to keeping airways open.¹⁸ Recessive forms can also affect internal organs, and several different genes beyond elastin have been implicated.

Epidermolysis Bullosa

Epidermolysis bullosa (EB) causes the skin to blister and tear from minimal friction or trauma. Different forms arise from mutations in different structural proteins at the junction between the outer skin layer and the tissue beneath it. Simplex forms involve mutations in keratins, junctional forms involve mutations in laminin genes, and dystrophic forms result from mutations in the type VII collagen gene.¹⁹ Severe forms, particularly recessive dystrophic and junctional EB, can be life-threatening due to chronic wounds, infection, scarring that fuses fingers or restricts the esophagus, and nutritional problems.²⁰

Alport Syndrome

Alport syndrome affects the basement membranes of the kidneys, inner ear, and eyes, and it is caused by mutations in the genes for type IV collagen (COL4A3, COL4A4, or COL4A5). It can be inherited in an X-linked, autosomal recessive, or autosomal dominant pattern, which means the severity and age of onset vary significantly depending on which gene is affected and whether one or both copies carry mutations.²¹ Progressive kidney failure is the most serious outcome, often accompanied by sensorineural hearing loss and eye abnormalities such as a cone-shaped lens.

Why Diagnosis Is So Difficult

One of the biggest practical challenges facing patients and clinicians is that these conditions overlap heavily. A 2010 analysis identified 36 heritable connective tissue disorders with shared features and organized them by both clinical presentation and causative genes.¹ A young person with joint hypermobility, a dilated aortic root, and stretch marks could plausibly have Marfan syndrome, Loeys-Dietz syndrome, hypermobile EDS, or something rarer. Relying on clinical criteria alone can lead to incorrect labels that carry real consequences for surveillance, treatment, and family planning.

Gene panel testing using next-generation sequencing has become the standard diagnostic tool for sorting through this overlap. In one cohort of 199 patients referred for hereditary aortic conditions, testing a panel of 32 genes yielded a definitive or likely pathogenic result in about 17% of cases.²² A separate study of 100 consecutive patients referred for connective tissue evaluation found pathogenic or likely pathogenic variants in about 10%, with another 35% receiving variants of uncertain significance, results that are essentially inconclusive.²³ Across broader connective tissue panels, pathogenic variants have been identified in roughly 9% of tested patients, with uncertain-significance variants appearing in an additional 19%.²⁴

These numbers illustrate a frustrating reality: even with state-of-the-art sequencing, most people referred for genetic evaluation of a suspected connective tissue disorder walk away without a clear molecular answer. The uncertain-significance category is particularly difficult to navigate because it means a variant was found, but current knowledge cannot confirm whether it actually causes disease. As databases of known variants grow larger and functional studies clarify what specific mutations do to proteins, the diagnostic yield is expected to improve. In the meantime, clinical evaluation by specialists who are deeply familiar with these conditions remains essential alongside genetic testing.

Daily Life and Quality of Life

The day-to-day burden of these disorders receives far less attention than the dramatic complications, but for many patients, chronic symptoms shape their quality of life more than any single medical crisis. People with hypermobile EDS and related hypermobility spectrum disorders consistently report poorer outcomes across every standard quality-of-life domain, including physical function, energy, pain, and general health perception.²⁵ Fatigue is a particularly prominent complaint, often severe enough to limit participation in work, education, and social life.

Women with hypermobility spectrum disorders and hypermobile EDS experience high rates of autonomic dysfunction, meaning problems with the involuntary nervous system that controls heart rate, blood pressure, digestion, and temperature regulation. These symptoms compound chronic pain and contribute to reduced quality of life.²⁶ The psychological toll is significant as well. Living with EDS and related conditions increases the likelihood of depression and anxiety, and the social consequences, including isolation, difficulty maintaining employment, and economic hardship, can be as disabling as the physical symptoms themselves.²⁷

For conditions diagnosed in childhood, such as Marfan syndrome and osteogenesis imperfecta, the transition from pediatric to adult healthcare is another underappreciated challenge. Pediatric care typically involves parents who coordinate appointments, manage medications, and advocate with insurers. When a teenager moves into the adult system, responsibility shifts simultaneously to the patient and to a new medical team that may have less experience with the condition. Studies of Marfan patients in transition describe this as a period of elevated risk, where follow-up can lapse and complications can go undetected.²⁸ Structured transition programs that gradually shift responsibility to the patient, with overlapping pediatric and adult care, appear to help but are not yet widely available.

Pregnancy and Reproductive Risk

Pregnancy amplifies the cardiovascular stresses that are already the primary threat in several of these disorders. The combination of increased blood volume, higher cardiac output, and hormonal changes that loosen connective tissue creates a period of heightened danger for the aorta and other large vessels. Women with Marfan syndrome, Loeys-Dietz syndrome, and vascular EDS all face substantially elevated risks during and shortly after pregnancy.²⁹

Vascular EDS deserves particular attention here. A systematic review found that women with vEDS face elevated risks of uterine rupture, vascular events, digestive events, and death during pregnancy.³⁰ These are not theoretical concerns but documented outcomes that demand careful preconception counseling. Decisions about whether and how to pursue pregnancy in the setting of a genetic connective tissue disorder are deeply personal, but they should be informed by multidisciplinary teams that include genetics specialists, high-risk obstetricians, and cardiovascular surgeons who understand the specific condition. Preimplantation genetic testing during in vitro fertilization is an option for couples who want to prevent transmission of a known mutation.

Gene Editing and the Research Horizon

For most of the conditions listed above, current treatments manage symptoms and slow progression without correcting the underlying genetic defect. Gene-editing technologies are beginning to change that picture, at least in early-stage research. CRISPR-based approaches have been explored for osteogenesis imperfecta, Alport syndrome, and dystrophic epidermolysis bullosa, among others.³¹

The basic idea is to use molecular tools that can find a specific spot in the genome and either cut out the faulty sequence, replace it with a correct one, or alter a single DNA letter to fix a point mutation. Newer techniques like base editing and prime editing can make these corrections without fully cutting the DNA strand, reducing the risk of unintended changes elsewhere in the genome. Preclinical studies in cell cultures and animal models have shown that these approaches can restore collagen production, improve tissue structure, and reduce symptoms. In epidermolysis bullosa, for example, researchers have demonstrated readthrough agents that can coax cells to ignore a premature stop signal in the collagen gene and produce functional protein.²⁰

Translating these laboratory successes into approved therapies for patients is a long road. Delivering the editing machinery to the right cells in the right tissues, doing so safely and permanently, and scaling production for a rare disease market are all unsolved problems. One approved gene therapy for dystrophic EB (beremagene geperpavec, a topical gel containing a viral vector carrying a correct copy of the COL7A1 gene) has already reached the clinic, but it treats wounds locally rather than correcting the underlying mutation body-wide. For systemic conditions like Marfan syndrome or osteogenesis imperfecta, where the defective protein is needed in tissues spread across the entire body, the delivery challenge is considerably steeper. Still, the pace of progress in gene editing has been rapid enough that conditions once considered permanently untreatable are now firmly in the preclinical pipeline.

1
Genetics in Medicine. Hereditary disorders of connective tissue: A guide to the emerging differential diagnosis
2
PubMed Central. Genetic Disorders of the Extracellular Matrix
3
Nature Reviews Disease Primers. The Ehlers–Danlos syndromes
4
PubMed. Hypermobile Ehlers-Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing
5
PubMed. Arterial complications of vascular Ehlers-Danlos syndrome
6
PubMed Central. The Molecular Genetics of Marfan Syndrome
7
Nature Genetics. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome
8
PubMed. The revised Ghent nosology for the Marfan syndrome
9
PubMed Central. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome
10
PubMed. Aneurysm syndromes caused by mutations in the TGF-beta receptor
11
The Turkish Journal of Pediatrics. Arterial tortuosity and aneurysm in a case of Loeys-Dietz syndrome type IB with a mutation p.R537P in the TGFBR2 gene
12
PubMed. TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome
13
PubMed Central. Osteogenesis imperfecta: advancements in genetics and treatment
14
PubMed Central. Hearing Loss in Stickler Syndrome: An Update
15
PubMed Central. ABCC6 and Pseudoxanthoma Elasticum: The Face of a Rare Disease from Genetics to Advocacy
16
PubMed. ABCC6 and pseudoxanthoma elasticum
17
PubMed Central. New insights into the pathogenesis of autosomal-dominant cutis laxa with report of five ELN mutations
18
PubMed. Autosomal dominant cutis laxa with severe lung disease: synthesis and matrix deposition of mutant tropoelastin
19
Journal of Investigative Dermatology. Genetic Connective Tissue Disorders: A List of Conditions
20
PubMed Central. Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa
21
Frontiers in Medicine. Genotype-Phenotype Correlations for Pathogenic COL4A3–COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome
22
Genetics in Medicine. Next-generation sequencing of 32 genes associated with hereditary aortopathies and related disorders of connective tissue in a cohort of 199 patients
23
PubMed Central. Clinical genetics evaluation and testing of connective tissue disorders: a cross-sectional study
24
PubMed. Diagnostics of Hereditary Connective Tissue Disorders by Genetic Next-Generation Sequencing
25
PubMed Central. Perceived quality of life, fatigue and the metabolic cost of walking in generalized hypermobility spectrum disorder and hypermobile Ehlers-Danlos syndrome
26
PubMed. Autonomic symptom burden, comorbidities and quality of life in women with Hypermobility Spectrum Disorders and hypermobile Ehlers-Danlos syndrome
27
PubMed Central. Quality of Life With Ehlers‐Danlos Syndrome/Joint Hypermobility Syndrome: A Systematic Review of Psychosocial Interventions
28
PubMed Central. The transition of pediatric Marfan patients to adult care: a challenge and its risks
29
PubMed Central. The Impact of Pregnancy in Patients with Thoracic Aortic Disease: Epidemiology, Risk Assessment, and Management Considerations
30
PubMed. Vascular Ehlers-Danlos syndrome and pregnancy: A systematic review
31
PubMed Central. Gene editing for collagen disorders: current advances and future perspectives